Ocugen Inc 2H51
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 2H51 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.40
- Day Range
- $1.41–1.41
- 52-Week Range
- $0.33–14.14
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $363.13 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 54.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 84
- Website
- https://www.ocugen.com
Comparables
Valuation
|
Metric
|
2H51
|
RYTM
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 12.96 | 42.34 | 0.60 |
Price/Sales | 54.79 | 27.23 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
2H51
RYTM
AVIR
Financial Strength
|
Metric
|
2H51
|
RYTM
|
AVIR
|
|---|---|---|---|
Quick Ratio | 1.64 | 3.99 | 13.11 |
Current Ratio | 1.87 | 4.35 | 13.28 |
Interest Coverage | — | −17.19 | — |
Quick Ratio
2H51
RYTM
AVIR
Profitability
|
Metric
|
2H51
|
RYTM
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | −66.72% | −77.30% | −20.62% |
Return on Equity (Normalized) | −91.20% | −148.97% | −21.76% |
Return on Invested Capital (Normalized) | −81.41% | −146.66% | −25.76% |
Return on Assets
2H51
RYTM
AVIR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Sdrhrpmbp | Tkktfl | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xqxfdkjtg | Rmfwzk | $114.2 Bil | |||
| Moderna Inc
MRNA
| Yxxnkwdw | Gzssx | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Hnlggzj | Jqyn | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vfqlddlb | Lbyr | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cvrmftyt | Lvmkhw | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nqlphvrkx | Hsnxt | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Fkczgvvfj | Ysjds | $12.8 Bil | |||
| Incyte Corp
INCY
| Zlknjqyb | Bxbrb | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Wjczwqlb | Mmkpscz | $12.2 Bil |